The estimated Net Worth of Mark N Wegman is at least $7.72 Million dollars as of 24 May 2019. Mark Wegman owns over 7,800 units of Biospecifics Technologies stock worth over $5,778,530 and over the last 6 years he sold BSTC stock worth over $1,758,417. In addition, he makes $187,507 as Director at Biospecifics Technologies.
Mark has made over 6 trades of the Biospecifics Technologies stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 7,800 units of BSTC stock worth $476,502 on 24 May 2019.
The largest trade he's ever made was exercising 15,000 units of Biospecifics Technologies stock on 15 May 2019 worth over $314,250. On average, Mark trades about 4,500 units every 28 days since 2018. As of 24 May 2019 he still owns at least 65,272 units of Biospecifics Technologies stock.
You can see the complete history of Mark Wegman stock trades at the bottom of the page.
Dr. Mark N. Wegman Ph.D. serves as Director of the Company. Dr. Wegman is currently the Chief Scientist Computing as a Service with worldwide responsibilities in IBM’s Research laboratories, where he joined in 1975. Dr. Wegman is recognized for his significant contributions to computer algorithms and compiler optimization that have deeply influenced many areas of computer science and practice. He is an IBM Fellow, a Fellow of the ACM and the IEEE, and the 2006 recipient of the IBM Programming Languages Achievement Award. He is also a member of the National Academy of Engineering. Dr. Wegman is the author of over 30 publications in the field of Computer Science. Dr. Wegman received his doctorate in Computer Science from the University of California at Berkeley and has been named a Distinguished Alumnus. Dr. Wegman is the son of our former CEO and Chairman, Edwin H. Wegman and the brother of our former President, Thomas Wegman. Dr. Wegman is the stepson of Toby Wegman, a current director of the Company. The Company believes that Dr. Wegman is qualified to serve as a member of our Board because of his business and professional experience in leadership roles.
As the Director of Biospecifics Technologies, the total compensation of Mark Wegman at Biospecifics Technologies is $187,507. There are 3 executives at Biospecifics Technologies getting paid more, with Jennifer Chao having the highest compensation of $217,507.
Mark Wegman is 70, he's been the Director of Biospecifics Technologies since 2007. There are 3 older and 5 younger executives at Biospecifics Technologies. The oldest executive at Biospecifics Technologies Corp. is Toby Wegman, 85, who is the Director.
Mark's mailing address filed with the SEC is C/O BIOSPECIFICS TECHNOLOGIES CORP., 2 RIGHTER PKWY, DE CORP CENTER II, WILMINGTON, DE, 19803.
Over the last 33 years, insiders at Biospecifics Technologies have traded over $67,860,045 worth of Biospecifics Technologies stock and bought 7,761,661 units worth $656,708,120 . The most active insiders traders include Capital Management, Llc Kol..., International Plc Endo, and Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of $6,538,649. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth $650,028,518.
Biospecifics Technologies executives and other stock owners filed with the SEC include: